These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 33210451)

  • 1. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
    Wang H; Xu Y; Lin J; Huang Y
    Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with
    Choudhury NJ; Schoenfeld AJ; Flynn J; Falcon CJ; Rizvi H; Rudin CM; Kris MG; Arcila ME; Heller G; Yu HA; Ladanyi M; Riely GJ
    Clin Cancer Res; 2021 May; 27(10):2920-2927. PubMed ID: 33685865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Clinical Outcomes for Patients with
    Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
    Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
    Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
    Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Takashima Y; Sakakibara-Konishi J; Hatanaka Y; Hatanaka KC; Ohhara Y; Oizumi S; Hida Y; Kaga K; Kinoshita I; Dosaka-Akita H; Matsuno Y; Nishimura M
    Clin Lung Cancer; 2018 Jul; 19(4):352-359.e1. PubMed ID: 29544718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
    Riess JW; Gandara DR; Frampton GM; Madison R; Peled N; Bufill JA; Dy GK; Ou SI; Stephens PJ; McPherson JD; Lara PN; Burich RA; Ross JS; Miller VA; Ali SM; Mack PC; Schrock AB
    J Thorac Oncol; 2018 Oct; 13(10):1560-1568. PubMed ID: 29981927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.